TKD activated natural killer cells

Drug Profile

TKD activated natural killer cells

Alternative Names: Activated autologous NK cells - multimmune; Enkastim-ev; Enkastim-iv; Heat shock protein 70 peptide activated natural killer cells; HSP70 peptide activated natural killer cells; Hsp70-peptide TKD/IL-2 activated, autologous NK cells; Natural killer cell therapy - multimmune

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator multimmune
  • Developer multimmune; Technical University Munich
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Colorectal-cancer(Metastatic disease, Second-line therapy or greater) in Germany (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Metastatic disease, Second-line therapy or greater) in Germany (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top